MedTrace Logo

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)

NCT02654470 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-11-19

No results posted yet for this study

Summary

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study

Conditions

  • Non-valvular Atrial Fibrillation

Interventions

DEVICE

Watchman FLX

Patients who are receiving the Watchman FLX device

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Timothy Betts · John Radcliffe Hospital, Oxford, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-16
Primary Completion
2021-09-28
Completion
2021-09-28

Countries

  • Denmark
  • France
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02654470 on ClinicalTrials.gov